Steffen D Kriechbaum1, Christoph B Wiedenroth2, Jan Sebastian Wolter3, Regula Hütz3, Moritz Haas3, Andreas Breithecker4, Fritz C Roller5, Till Keller3, Stefan Guth2, Andreas Rolf6, Christian W Hamm6, Eckhard Mayer2, Christoph Liebetrau6. 1. Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany; German Center for Cardiovascular Research, Partner Site Rhine-Main, Frankfurt am Main, Germany. Electronic address: s.kriechbaum@kerckhoff-klinik.de. 2. Department of Thoracic Surgery, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany. 3. Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany; German Center for Cardiovascular Research, Partner Site Rhine-Main, Frankfurt am Main, Germany. 4. Department of Radiology, Gesundheitszentrum Wetterau, Bad Nauheim, Germany. 5. Department of Radiology, Justus Liebig University Giessen, Giessen, Germany. 6. Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany; German Center for Cardiovascular Research, Partner Site Rhine-Main, Frankfurt am Main, Germany; Medical Clinic I, Division of Cardiology, Justus Liebig University Giessen, Giessen, Germany.
Abstract
BACKGROUND: Balloon pulmonary angioplasty (BPA) is an emerging interventional treatment option for chronic thromboembolic pulmonary hypertension (CTEPH). The non-invasive monitoring of CTEPH patients is a clinical challenge. In this study we examined changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients undergoing BPA for inoperable CTEPH and related them to peri-procedural success. METHODS: In this study we analyzed a total of 51 consecutive patients who underwent BPA treatment and completed a 6-month follow-up (6-MFU) between March 2014 and March 2017. Serum samples for NT-proBNP measurement were collected before every BPA and at 6-MFU. RESULTS: The 51 patients underwent 265 interventions involving angioplasty of a total of 410 vessels. The 6-month survival rate was 96.1%. The baseline (BL) mean pulmonary artery pressure (PAP) was 39.5 ± 12.1 mm Hg, pulmonary vascular resistance (PVR) was 515.8 ± 219.2 dynes/s/cm5 and the median NT-proBNP level was 820 (153 to 1,871.5) ng/liter. At BL, World Health Organization functional class (FC) was ≥III in 96.1% of the patients, whereas, at 6-MFU, 11.8% were in WHO FC ≥III. At 6-MFU, mean PAP (32.6 ± 12.6 mm Hg; p < 0.001), PVR (396.9 ± 182.6 dynes/s/cm5; p < 0.001) and NT-proBNP (159.3 [84.4 to 464.3] ng/liter; p < 0.001) levels were reduced. The decrease in NT-proBNP levels correlated with the decrease in mean PAP (rrs = 0.43, p = 0.002) and PVR (rrs = 0.50, p = 0.001). A reduction in the NT-proBNP level of 46% indicated a decrease in mean PAP of ≥25% (area under the curve [AUC] = 0.71) and a reduction of 61% indicated a decrease in PVR of ≥35% (AUC 0.77). CONCLUSIONS: Our results demonstrate that NT-proBNP levels decrease after BPA, providing valuable evidence of procedural success. NT-proBNP measurement allows identification of patients who are BPA non-responders and may thus be a valuable adjunct in therapy monitoring.
BACKGROUND:Balloon pulmonary angioplasty (BPA) is an emerging interventional treatment option for chronic thromboembolic pulmonary hypertension (CTEPH). The non-invasive monitoring of CTEPHpatients is a clinical challenge. In this study we examined changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients undergoing BPA for inoperable CTEPH and related them to peri-procedural success. METHODS: In this study we analyzed a total of 51 consecutive patients who underwent BPA treatment and completed a 6-month follow-up (6-MFU) between March 2014 and March 2017. Serum samples for NT-proBNP measurement were collected before every BPA and at 6-MFU. RESULTS: The 51 patients underwent 265 interventions involving angioplasty of a total of 410 vessels. The 6-month survival rate was 96.1%. The baseline (BL) mean pulmonary artery pressure (PAP) was 39.5 ± 12.1 mm Hg, pulmonary vascular resistance (PVR) was 515.8 ± 219.2 dynes/s/cm5 and the median NT-proBNP level was 820 (153 to 1,871.5) ng/liter. At BL, World Health Organization functional class (FC) was ≥III in 96.1% of the patients, whereas, at 6-MFU, 11.8% were in WHO FC ≥III. At 6-MFU, mean PAP (32.6 ± 12.6 mm Hg; p < 0.001), PVR (396.9 ± 182.6 dynes/s/cm5; p < 0.001) and NT-proBNP (159.3 [84.4 to 464.3] ng/liter; p < 0.001) levels were reduced. The decrease in NT-proBNP levels correlated with the decrease in mean PAP (rrs = 0.43, p = 0.002) and PVR (rrs = 0.50, p = 0.001). A reduction in the NT-proBNP level of 46% indicated a decrease in mean PAP of ≥25% (area under the curve [AUC] = 0.71) and a reduction of 61% indicated a decrease in PVR of ≥35% (AUC 0.77). CONCLUSIONS: Our results demonstrate that NT-proBNP levels decrease after BPA, providing valuable evidence of procedural success. NT-proBNP measurement allows identification of patients who are BPA non-responders and may thus be a valuable adjunct in therapy monitoring.
Authors: Muhammad Shahzeb Khan; Emaan Amin; Muhammad Mustafa Memon; Naser Yamani; Tariq Jamal Siddiqi; Safi U Khan; Mohammad Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Rami Doukky; Raymond L Benza; Richard A Krasuski Journal: Int J Cardiol Date: 2019-02-23 Impact factor: 4.164
Authors: F C Roller; S Kriechbaum; A Breithecker; C Liebetrau; M Haas; C Schneider; A Rolf; S Guth; E Mayer; C Hamm; G A Krombach; C B Wiedenroth Journal: Eur Radiol Date: 2018-08-29 Impact factor: 5.315
Authors: Christoph B Wiedenroth Md; Andreas J Rieth Md; Steffen Kriechbaum Md; H-Ardeschir Ghofrani Md; Andreas Breithecker Md; Moritz Haas Md; Fritz Roller Md; Manuel J Richter Md; Mareike Lankeit; Lisa Mielzarek; Andreas Rolf Md; Christian W Hamm Md; Eckhard Mayer Md; Stefan Guth Md; Christoph Liebetrau Md Journal: Pulm Circ Date: 2020-08-18 Impact factor: 3.017
Authors: Steffen D Kriechbaum; Lillith Scherwitz; Christoph B Wiedenroth; Felix Rudolph; Jan-Sebastian Wolter; Moritz Haas; Ulrich Fischer-Rasokat; Andreas Rolf; Christian W Hamm; Eckhard Mayer; Stefan Guth; Till Keller; Stavros V Konstantinides; Mareike Lankeit; Christoph Liebetrau Journal: ERJ Open Res Date: 2020-11-02
Authors: Marta Banaszkiewicz; Arkadiusz Pietrasik; Michał Florczyk; Piotr Kędzierski; Michał Piłka; Rafał Mańczak; Janusz Kochman; Grzegorz Opolski; Adam Torbicki; Marcin Kurzyna; Szymon Darocha Journal: Diagnostics (Basel) Date: 2021-01-16
Authors: Steffen D Kriechbaum; Christoph B Wiedenroth; Till Keller; Jan Sebastian Wolter; Ruth Ajnwojner; Karina Peters; Moritz A Haas; Fritz C Roller; Andreas Breithecker; Andreas J Rieth; Stefan Guth; Andreas Rolf; Dirk Bandorski; Christian W Hamm; Eckhard Mayer; Christoph Liebetrau Journal: PLoS One Date: 2018-09-25 Impact factor: 3.240
Authors: Steffen D Kriechbaum; Felix Rudolph; Christoph B Wiedenroth; Lisa Mielzarek; Moritz Haas; Stefan Guth; Christian W Hamm; Eckhard Mayer; Christoph Liebetrau; Till Keller Journal: Respir Res Date: 2020-08-03
Authors: M C J van Thor; R J Lely; N J Braams; L Ten Klooster; M A M Beijk; R H Heijmen; D A F van den Heuvel; B J W M Rensing; R J Snijder; A Vonk Noordegraaf; E J Nossent; L J Meijboom; P Symersky; J J Mager; H J Bogaard; M C Post Journal: Neth Heart J Date: 2020-02 Impact factor: 2.380